- Trial phase
- Phase 2b
- Time to market
- If the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.
- Why 4/10
- The next hard, dated catalyst is the Phase 2b ADAPTIVE topline data readout in atopic dermatitis, expected in Q4 2027, which is more than 12 months away. With no nearer binary catalyst, the impact score is capped at 4 despite olevaprubart being the company's sole pipeline asset.
The next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.
Price Chart
Executive Summary
Olevaprubart (IMG-007) is ImageneBio's sole pipeline asset, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life being developed for atopic dermatitis and alopecia areata. The Phase 2b ADAPTIVE trial in atopic dermatitis is ongoing with topline data expected in Q4 2027, while a Phase 2 alopecia areata study is on track to start by year-end 2026. Phase 2a data showed rapid, durable improvement with a well-tolerated profile. The OX40 competitive landscape is mixed: rocatinlimab (Amgen/Kyowa Kirin) has positive Phase 3 data, but Sanofi abandoned amlitelimab in atopic dermatitis and AbCellera exited the space. With $126.6M cash, no near-term binary catalyst, and a wide analyst target range ($2-$28), the stock ($3.72) reflects deep uncertainty about the drug's prospects until the ADAPTIVE readout in late 2027.
How It Works
Olevaprubart is an antibody that blocks the OX40 receptor on immune T cells. OX40 acts like an 'on' switch for inflammatory T cells that drive diseases like eczema (atopic dermatitis) and alopecia areata (hair loss). By blocking OX40 without killing the T cells (non-T cell-depleting) and with a modified tail that avoids certain immune side effects (ADCC-silenced), the drug aims to calm the overactive immune response. Its extended half-life means patients may need less frequent dosing.
Trial Status
The Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis is actively enrolling in North America under an amended protocol. Topline data is expected in Q4 2027. A Phase 2 study in alopecia areata is on track to initiate by year-end 2026 with initial data expected in 2028. Phase 2a data in both indications have been reported: positive interim results in atopic dermatitis (Jan 2025) and positive topline results in alopecia areata (Apr 2025).
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 2 alopecia areata study by year-end 2026
- Phase 2b ADAPTIVE topline data in atopic dermatitis expected Q4 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ImageneBio, Inc. 8-K IMA ·Originating report